Melanoma Clinical Trials in Georgia

Showing 161-180 of 293 trials

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

NCT04348916

ONCR-177-101 is a phase 1, open-label, multi-center, dose escalation and expansion study of ONCR-177, an oncolytic Herpes Simplex Virus for intratumoral injection, alone and in combination with PD-1 blockade in adult subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors or with Liver Metastases of Solid Tumors. The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

CancerMelanomaSolid Tumor+7 more

Oncorus, Inc.66 participantsStarted May 2020

Duarte, California, United States • Denver, Colorado, United States • Tampa, Florida, United States +8 more locations

COMPLETEDPhase 165 miles

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

NCT03849469

This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.

MelanomaCervical CarcinomaPancreatic Carcinoma+20 more

Xencor, Inc.78 participantsStarted May 2019

Encinitas, California, United States • La Jolla, California, United States • La Jolla, California, United States +25 more locations

PreviousPage 9 of 15Next

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Melanoma Trials in Other Cities

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Safety Study of SEA-CD40 in Cancer Patients

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Study of ASN003 in Subjects With Advanced Solid Tumors

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)

A Study of PLX2853 in Advanced Malignancies.

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Other Conditions in Georgia